Latest From Biotech Now

GMO Answers on the IARC Assessment of 2,4-D as a Possible Carcinogen

GMO Answers

The International Agency for Research on Cancer (IARC) creates Working Groups to periodically consider lifestyles, workplaces, and compounds that may have carcinogenicity potential. IARC is an agency under the World Health Organization (WHO) but is not responsible for regulating pesticides. On Monday, IARC classified 2,4-D as “possibly carcinogenic” to humans (Group 2B — same category as coffee and carpentry). Will this classification affect your daily life? Most likely — no. What is 2,4-D? 2,4-D is Read More >

Food And Agriculture, Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

ASCO Publishes New “Value Framework” for Cancer Treatment Options

medicine

On Monday, the American Society of Clinical Oncology (ASCO) published “A Framework to Assess the Value of Cancer Treatment Options” in the Journal of Clinical Oncology intended to ‘assess the value of new cancer therapies based on treatment benefits, toxicities, and costs.’ The framework, developed by the ASCO Value in Cancer Care Task Force, is intended to ‘ultimately serve as the basis for user-friendly, standardized tools that physicians can use with their patients to discuss the relative value Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma

patent

The Intellectual Property Track at the BIO International Convention was a chance for IP thought leaders in the biotech sector to discuss some of the most pressing issues impacting the industry. Let’s recap what we learned from one of the IP sessions at BIO 2015: The Impact of IPRs on (BIO)Pharma On Tuesday, patent litigation experts met to discuss inter partes review proceedings and how they are impacting biotechnology. Panelists from The Impact of IPRs Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,

FDA Acts on Biosimilars

Noonan-Headshot-high-res

The Biologics Price Competition and Innovation Act (BPCIA) deferred to the Food and Drug Administration with regard to implementing the particulars of how the biosimilar approval pathway would be implemented.  The U.S. Food and Drug Administration has issued a series of draft Guidances indicating how it was considering implementing the biosimilar approval pathway contained in the Act.  The Guidances were expressly “draft” in nature, and were the subject of public hearings with the Agency welcoming Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Driving to Drive Women in Ag Business

American Agri-Women 40th Anniversary

On June 1 in Easton, ME, American Agri-Women (AAW) set out on a 5 month long drive across the USA to celebrate their 40th anniversary and women’s roles in agriculture. Making stops at major cities like Washington D.C., the AAW strives to amplify the conversation between farmers, consumers, the media and lawmakers at their delicious BBQs, farm visits, manufacturing tours and other public events! Their drive will finish in November when they arrive at their annual convention Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , ,